<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591808</url>
  </required_header>
  <id_info>
    <org_study_id>CL3-05167-005</org_study_id>
    <nct_id>NCT04591808</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia</brief_title>
  <official_title>Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia, 8 Weeks, Phase 3, Randomized, Double-blind, Active-control, Multinational, Multi-center, Parallel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of atorvastatin/perindopril fixed&#xD;
      dose combination (FDC) S05167 as compared to atorvastatin reference drug alone or perindopril&#xD;
      drug alone on systolic blood pressure decrease and LDL cholesterol decrease respectively in&#xD;
      patients presenting with hypertension and dyslipidemia after 8 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure (SBP)</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Mean change from baseline in sitting systolic blood pressure (SBP) in the S05167 group as compared with the Lipitor group (in terms of superiority)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-Density Lipoprotein Cholesterol (LDLc)</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Percent of change from baseline in Low-Density Lipoprotein Cholesterol (LDLc) in the S05167 group as compared with the Coversyl group (in terms of superiority)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure (SBP)</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Mean change from baseline in sitting systolic blood pressure (SBP) in the S05167 group as compared with Coversyl group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density Lipoprotein Cholesterol (LDLc)</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Percent of change from baseline in Low-Density Lipoprotein Cholesterol (LDLc) level in the S05167 group as compared with the Lipitor group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure (DBP)</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Mean change from baseline in diastolic blood pressure (DBP) in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Pressure</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Mean change from baseline Pulse Pressure in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Percent of Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure response</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Percent of responders (in terms of blood pressure response defined by patients with BP&lt; 140/90 mm Hg or SBP decrease &gt; = 20 mm Hg or DBP decrease &gt; =10 mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Percent of blood pressure control: BP&lt; 140/80 mm Hg AND % of blood pressure control: BP &lt; 130/80 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids control</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Percent of responders (in terms of lipids control: an absolute reduction to an LDLc level&lt; 2.6 mmol/L [100 mg/dL] or a reduction at least 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and Serious adverse events (SAE)</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Emergent Adverse events and Serious adverse events (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Blood pressure (BP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Pulse rate (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Respiratory rate (RR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Significant abnormalities observed from ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical lab tests</measure>
    <time_frame>Over 8 weeks</time_frame>
    <description>Relevant deviations of laboratory test results</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">545</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>S05167</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipitor®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Coversyl®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin/Perindopril</intervention_name>
    <description>1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.</description>
    <arm_group_label>S05167</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.</description>
    <arm_group_label>Lipitor®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.</description>
    <arm_group_label>Coversyl®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women from 18 to 79 years old who can comply with the study requirements and&#xD;
             timetable,&#xD;
&#xD;
          2. Patients diagnosed with Essential hypertension (as documented in patient's medical&#xD;
             file). The diagnosis of hypertension should be based on at least two BP measurements&#xD;
             on at least two visits.&#xD;
&#xD;
             Uncontrolled hypertensive patients currently under monotherapy treatment within at&#xD;
             least 4 weeks (except patients treated by perindopril) for combined systolic and&#xD;
             diastolic hypertension (140 mmHg ≤ SBP &lt; 160 mmHg and 90 mmHg ≤ DBP &lt; 100 mmHg).&#xD;
&#xD;
             or Hypertensive patients naïve of treatment with 150 mmHg ≤ SBP &lt;160 mmHg and 90 mmHg&#xD;
             ≤ DBP &lt; 100 mmHg.&#xD;
&#xD;
          3. Dysplipidemic patients: naïve of treatment or uncontrolled with statin at lowest dose&#xD;
             within at least 4 weeks with 110 mg/ Decilitre (dL) (or 2.84 millimole [mmol] /L) ≤&#xD;
             LDL-c &lt; 190 mg/dL (or 4.91 mmol/L) according to a previous laboratory result within 12&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unlikely to cooperate in the study,&#xD;
&#xD;
          2. Pregnant and lactating women,&#xD;
&#xD;
        4. Participation in another study at the same time or having participated in another study&#xD;
        within 3 months before selection participation in noninterventional registries or&#xD;
        epidemiological studies is allowed,&#xD;
&#xD;
        6.Patients treated with &gt;1 anti-hypertensive drug or &gt;1 Lipid lowering drug,&#xD;
&#xD;
        7.Patients previously treated with atorvastatin and/or perindopril,&#xD;
&#xD;
        8.Known resistance to ACE inhibitors,&#xD;
&#xD;
        9.Patients treated with beta-blockers or alpha-blockers,&#xD;
&#xD;
        10. Patients with liver disease or renal impairment,&#xD;
&#xD;
        11.Certain known cardiovascular diseases or cardiac rhythm disorders,&#xD;
&#xD;
        12.Known or suspected symptomatic orthostatic hypotension,&#xD;
&#xD;
        13.Familial hypercholesterolemia,&#xD;
&#xD;
        14.Secondary hypertension or dyslipidemia,&#xD;
&#xD;
        15.Patients who are hypersensitive to atorvastatin, perindopril or to any of the excipients&#xD;
        of study drugs,&#xD;
&#xD;
        16.Hypersensitivity to any other ACE inhibitor,&#xD;
&#xD;
        17.History of angioedema associated with previous ACE inhibitor therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier, Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LTD &quot;Clinic-LJ&quot;</name>
      <address>
        <city>Kutaisi</city>
        <zip>46000</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD &quot;Marnecore&quot;</name>
      <address>
        <city>Marneuli</city>
        <zip>3000</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Aleksandre Aladashvili Clinic&quot; LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>01102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Israel-Georgian Medical Research Clinic &quot;Helsicore&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>01112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bokhua Memorial Cardiovascular Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd &quot;Digomi Medical Center&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD &quot;MediClubGeorgia&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Cardiology Center n.a. Acad G Chapidze</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSI &quot;Northern Medical Clinical Centre n.a. N.A. Semashko FMBA of Russia&quot;</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Сity clinical hospital #1 named after E.E.Volosevich</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Institution of Healthcare &quot;Railway Clinical Hospital at station Chelyabinsk of open joint-stock company &quot;Russian Railways&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;National Medical Research Center for Preventive Medicine&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Moscow &quot;City Clinical Hospital #51&quot; of Department of Healthcare of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Orenburg State Medical University&quot; based on Municipal State healthcare Institution &quot;City Hospital emergency # 1&quot; of the city of Orenburg</name>
      <address>
        <city>Orenburg</city>
        <zip>460040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;Penza Regional Clinical Hospital n.a. N.N. Burdenko&quot;</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary institution &quot;Ryazan' regional clinical hospital&quot;</name>
      <address>
        <city>Ryazan'</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg state budgetary institution of healthcare &quot;City policlinic #109&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192289</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;North-Western State Medical University named after I.I. Mechnikov&quot; , the department faculty and hospital care, court number 5</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Institute, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPB SBHI &quot;City Hospital # 38 n.a. N.A. Semashko&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg GUZ &quot;City Hospital #40 of the Resort District&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Institution of Health &quot;City Hospital № 15&quot; Cardiology Care Unit</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Institution of Healthcare &quot;Diagnostic center #85&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPB SBHI &quot;Pokrovskaya City Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov Research Cardiology Institute of Roszdrav</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary institutionof heath of Tver region &quot;Region clinical hospital&quot;</name>
      <address>
        <city>Tver</city>
        <zip>166036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare Vladimir region ''City Hospital № 4 of Vladimir &quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary institution of heath of Yaroslavl region &quot;Regional clinical hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution &quot;Ivano-Frankivsk National Medical University&quot;, Chair of Internal Medicine #2 and Nursing based on Communal Institution Ivano-Frankivsk Regional Clinical Cardiological Center, Chronic Ischaemic Heart Disease Department</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>vano-Frankivsk central city clinical hospital, Cardiology department</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;L.T. Malaya Therapy National Institute of the National Institute of Medical Science of Ukraine&quot; Department of aging and prevention of metabolic-associated diseases</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Railway Clinical Hospital #1 of Branch &quot;Health Center&quot; of Public Joint Stock Company &quot;Ukrainian Railway&quot;. Cardiology Department #1</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Training and Research Medical Complex &quot;The University Clinic&quot; of the Kharkiv National Medical University, Department of Therapy, National Pharmaceutical University, Chair of Pharmacotherapy</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Institute of gerontology named after D.F. Chebotaryov НAMS of Ukraine, Department of Clinical and Epidemiological Cardiology</name>
      <address>
        <city>Kiev</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center ''CONSILIUM MEDICAL''</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danylo Halytskyi Lviv National Medical University Department of Therapy No. 1 and Medical Diagnostics of the Faculty of Postgraduate Education</name>
      <address>
        <city>Lviv</city>
        <zip>79059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Propedeutic of Internal Medicine #1 of Danylo Halytsky Lviv National Medical University based Municipal Non-profit Enterprise &quot;Lviv City Clinical Hospital #5&quot; Out-patient department.</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical and Diagnostic Center of LLC &quot;House of Medicine&quot;</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Internal Medicine #3 of Ternopil National Medical University named after I. Gorbachevsky of MOH of Ukraine based on Outpatient Department of Municipal Institution of Ternopil Regional Council &quot;Ternopil University Hospital&quot;,</name>
      <address>
        <city>Ternopil'</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise Ternopil University Hospital of Ternopil Regional Council, Department of Rheumatology, I. Horbachevsky Ternopil National Medical University of MOH of Ukraine, Chair of Internal Medicine #2</name>
      <address>
        <city>Ternopil'</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Institution &quot;Vinnytsya City Clinical Hospital #1&quot;, Therapeutical department; National Pirogov Memorial University, Vinnytsya, Chair of Propedeutics of Internal Medicine;</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Small-Scale Enterprise Medical Center &quot;Pulse&quot;</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Perindopril</keyword>
  <keyword>HMG-CoA reductase inhibitor</keyword>
  <keyword>ACE inhibitor</keyword>
  <keyword>Fixed combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>[study-level clinical trial data]</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

